C55_contig_1272_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.0	219	224	228	2.51e-42	142
C55_contig_1272_32	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	224	224	231	2.15e-41	139
C55_contig_1272_32	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.5	224	224	232	6.91e-40	135
C55_contig_1272_32	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.4	221	224	219	5.43e-39	133
C55_contig_1272_32	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	218	224	220	2.21e-38	131
C55_contig_1272_32	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	218	224	219	3.03e-38	131
C55_contig_1272_32	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	218	224	219	4.28e-38	130
C55_contig_1272_32	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	218	224	220	4.39e-38	130
C55_contig_1272_32	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.8	229	224	231	7.17e-36	125
C55_contig_1272_32	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.8	229	224	231	1.01e-35	125
C55_contig_1272_33	CARD|gb|AEX49906.1|ARO:3003583|basS	24.7	235	348	477	1.38e-18	85.5
C55_contig_1272_33	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.0	250	348	359	4.45e-18	83.2
C55_contig_1272_33	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.1	264	348	364	6.36e-15	73.9
C55_contig_1272_33	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.1	264	348	364	6.36e-15	73.9
C55_contig_1272_73	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	1.02e-118	367
C55_contig_1272_73	SARG|gb|AKA86814|ARO:3003746|optrA	34.8	624	638	655	1.02e-118	367
C55_contig_1272_73	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	3.99e-118	365
C55_contig_1272_73	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	3.99e-118	365
C55_contig_1272_73	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	5.62e-118	365
C55_contig_1272_73	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	7.91e-118	364
C55_contig_1272_73	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	7.91e-118	364
C55_contig_1272_73	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	1.11e-117	364
C55_contig_1272_73	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	1.11e-117	364
C55_contig_1272_73	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	1.57e-117	363
C55_contig_1272_142	SARG|gb|AAB53445.1|ARO:3002897|SAT-4	27.9	104	175	180	8.95e-07	45.8
C55_contig_1272_142	megares|MEG_6169|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	27.9	104	175	180	8.95e-07	45.8
C55_contig_1272_142	NCBI|WP_000627290.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	27.9	104	175	180	8.95e-07	45.8
C55_contig_1272_142	megares|MEG_6166|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	27.9	104	175	180	8.95e-07	45.8
C55_contig_1272_145	SARG|gi|921979807|ref|WP_053271336.1|	38.0	234	234	648	3.66e-48	166
C55_contig_1272_145	SARG|gi|895865878|ref|WP_048974758.1|	38.6	223	234	646	6.72e-47	163
C55_contig_1272_145	SARG|gb|AAV85982.1|ARO:3000535|macB	35.9	231	234	644	1.26e-46	162
C55_contig_1272_145	SARG|gi|694064328|ref|WP_032410816.1|	37.7	223	234	646	1.73e-45	159
C55_contig_1272_145	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.4	226	234	575	6.82e-19	84.0
C55_contig_1272_145	SARG|gb|AAK76137.1|ARO:3000024|patA	29.0	210	234	564	1.91e-17	79.7
C55_contig_1272_145	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.1	224	234	578	8.80e-17	77.8
C55_contig_1272_145	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.1	227	234	664	1.90e-15	73.9
C55_contig_1272_145	SARG|gi|493394434|ref|WP_006350564.1|	27.4	226	234	602	8.34e-15	72.0
C55_contig_1272_145	SARG|gi|655401130|ref|WP_028800283.1|	28.9	232	234	599	5.08e-14	69.7
C55_contig_1272_158	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.1	226	224	232	3.15e-44	147
C55_contig_1272_158	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.0	228	224	232	2.21e-41	139
C55_contig_1272_158	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	228	224	232	2.21e-41	139
C55_contig_1272_158	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.6	234	224	235	2.40e-41	139
C55_contig_1272_158	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	224	231	2.40e-40	137
C55_contig_1272_158	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	224	231	3.38e-40	136
C55_contig_1272_158	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.7	226	224	229	6.38e-40	135
C55_contig_1272_158	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.4	227	224	231	6.73e-40	135
C55_contig_1272_158	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	224	231	6.73e-40	135
C55_contig_1272_158	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	227	224	231	6.73e-40	135
C55_contig_1272_159	CARD|gb|ABD30512.1|ARO:3000839|arlS	32.4	219	552	451	2.00e-28	117
C55_contig_1272_159	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.6	223	552	370	2.53e-25	106
C55_contig_1272_159	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.4	246	552	392	2.24e-23	101
C55_contig_1272_159	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.5	219	552	381	2.88e-22	97.8
C55_contig_1272_159	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.5	219	552	381	2.88e-22	97.8
C55_contig_1272_159	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.3	223	552	365	2.06e-20	92.0
C55_contig_1272_159	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	219	552	381	2.44e-20	92.0
C55_contig_1272_159	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	219	552	381	2.44e-20	92.0
C55_contig_1272_159	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.9	213	552	885	5.77e-11	64.3
C55_contig_1272_162	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	35.0	220	238	293	5.65e-45	151
C55_contig_1272_162	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	34.7	222	238	307	3.15e-44	149
C55_contig_1272_162	SARG|gi|500194536|ref|WP_011867743.1|	34.8	221	238	306	5.63e-41	141
C55_contig_1272_169	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	221	227	219	6.06e-45	148
C55_contig_1272_169	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	221	227	219	1.21e-44	147
C55_contig_1272_169	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	221	227	220	1.24e-44	147
C55_contig_1272_169	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	221	227	220	1.76e-44	147
C55_contig_1272_169	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	221	227	220	9.89e-44	145
C55_contig_1272_169	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.2	222	227	219	5.41e-43	143
C55_contig_1272_169	SARG|ZP_02848503	33.5	221	227	221	1.01e-40	137
C55_contig_1272_169	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	31.7	227	227	232	4.46e-35	123
C55_contig_1272_169	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	34.0	206	227	223	7.04e-35	122
C55_contig_1272_169	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.8	232	227	232	1.92e-33	119
C55_contig_1272_174	SARG|gi|445996710|ref|WP_000074565.1|	28.7	223	299	309	1.45e-30	115
C55_contig_1272_174	SARG|gi|446110087|ref|WP_000187942.1|	28.2	234	299	309	3.92e-30	114
C55_contig_1272_174	SARG|gi|895736250|emb|COF64653.1|	28.3	223	299	309	5.46e-30	114
C55_contig_1272_174	SARG|gi|445996722|ref|WP_000074577.1|	28.7	223	299	309	5.46e-30	114
C55_contig_1272_174	SARG|gi|895808656|emb|COR83787.1|	28.3	223	299	309	5.46e-30	114
C55_contig_1272_174	SARG|gi|445996714|ref|WP_000074569.1|	28.3	223	299	309	7.60e-30	114
C55_contig_1272_174	SARG|gi|445996723|ref|WP_000074578.1|	28.7	223	299	309	7.60e-30	114
C55_contig_1272_174	SARG|gi|445996719|ref|WP_000074574.1|	28.7	223	299	309	1.06e-29	113
C55_contig_1272_174	SARG|gi|445996724|ref|WP_000074579.1|	28.7	223	299	309	1.06e-29	113
C55_contig_1272_174	SARG|gi|884875933|emb|CKG93789.1|	28.7	223	299	309	1.06e-29	113
C55_contig_1272_191	SARG|DQ212986.1.gene3.p01	52.2	67	70	75	8.76e-20	73.9
C55_contig_1272_223	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.4	656	659	885	2.32e-79	269
C55_contig_1272_223	CARD|gb|AEX49906.1|ARO:3003583|basS	25.9	239	659	477	6.76e-16	79.7
C55_contig_1272_223	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.1	220	659	361	4.48e-11	63.9
C55_contig_1272_224	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.9	225	234	225	4.66e-64	197
C55_contig_1272_224	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.9	225	234	225	4.66e-64	197
C55_contig_1272_224	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.9	222	234	219	6.75e-43	143
C55_contig_1272_224	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.5	228	234	231	7.44e-42	141
C55_contig_1272_224	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.1	226	234	232	1.52e-41	140
C55_contig_1272_224	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.1	226	234	232	1.52e-41	140
C55_contig_1272_224	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.2	223	234	231	6.52e-40	136
C55_contig_1272_224	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.8	228	234	232	6.69e-40	136
C55_contig_1272_224	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.3	223	234	228	1.20e-39	135
C55_contig_1272_224	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.5	222	234	229	1.23e-39	135
C55_contig_1272_243	CARD|gb|CYF42523.1|ARO:3004047|kdpD	44.2	165	189	885	1.30e-41	147
C55_contig_822_11	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.2	277	383	355	6.54e-20	89.0
C55_contig_822_11	SARG|BAE96115	29.2	277	383	355	6.54e-20	89.0
C55_contig_822_11	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.9	277	383	355	3.01e-19	87.0
C55_contig_822_11	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.9	277	383	355	3.01e-19	87.0
C55_contig_822_11	SARG|ACM47285	28.9	277	383	363	3.24e-19	87.0
C55_contig_822_11	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	31.4	194	383	209	1.68e-14	70.9
C55_contig_822_45	SARG|gi|851928815|ref|WP_048221086.1|	24.6	207	249	648	6.66e-11	60.8
C55_contig_822_45	SARG|gi|780033092|ref|WP_045444768.1|	24.6	207	249	648	6.66e-11	60.8
C55_contig_822_45	SARG|gi|992380339|ref|WP_061067665.1|	24.5	208	249	648	8.97e-11	60.5
C55_contig_822_45	SARG|gi|968563772|ref|WP_058587854.1|	23.8	210	249	648	1.62e-10	59.7
C55_contig_822_45	SARG|gi|922960663|ref|WP_053388845.1|	24.4	205	249	648	1.62e-10	59.7
C55_contig_822_45	SARG|gb|AAV85982.1|ARO:3000535|macB	23.3	202	249	644	2.18e-10	59.3
C55_contig_822_45	SARG|gi|757799695|ref|WP_043016897.1|	24.4	205	249	648	2.18e-10	59.3
C55_contig_822_45	SARG|gi|1045891604|ref|WP_065554100.1|	24.4	205	249	648	2.18e-10	59.3
C55_contig_822_45	SARG|gi|507082903|ref|WP_016153652.1|	24.4	205	249	648	2.18e-10	59.3
C55_contig_822_45	SARG|gi|696368937|ref|WP_032943949.1|	24.5	204	249	648	2.93e-10	58.9
C55_contig_822_50	SARG|gi|1035670474|ref|WP_064517458.1|	32.0	244	475	648	2.90e-24	105
C55_contig_822_50	SARG|gi|1035717981|ref|WP_064557480.1|	32.0	244	475	648	2.90e-24	105
C55_contig_822_50	SARG|gi|495736522|ref|WP_008461101.1|	33.0	230	475	648	3.88e-24	104
C55_contig_822_50	SARG|gi|746253210|ref|WP_039301529.1|	33.0	230	475	648	5.18e-24	104
C55_contig_822_50	SARG|gi|1001720867|ref|WP_061274204.1|	33.0	230	475	648	6.93e-24	103
C55_contig_822_50	SARG|gi|671541568|ref|WP_031525212.1|	34.1	220	475	648	2.95e-23	102
C55_contig_822_50	SARG|gi|751930065|ref|WP_041144773.1|	33.0	227	475	648	2.95e-23	102
C55_contig_822_50	SARG|gi|495067432|ref|WP_007792257.1|	32.7	220	475	647	3.93e-23	101
C55_contig_822_50	SARG|gi|746243059|ref|WP_039291473.1|	32.2	230	475	648	7.02e-23	100
C55_contig_822_50	SARG|gi|639216333|ref|WP_024554080.1|	32.7	223	475	648	1.67e-22	99.8
C55_contig_822_59	SARG|YP_002861121	47.4	57	200	212	4.61e-09	53.1
C55_contig_822_59	SARG|CAP74085	33.3	87	200	210	4.06e-08	50.4
C55_contig_822_59	SARG|U19459.gene.p01	38.6	57	200	212	5.78e-06	44.3
C55_contig_822_99	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	36.2	312	304	343	7.18e-56	183
C55_contig_822_99	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	38.6	220	304	325	1.20e-48	164
C55_contig_822_99	SARG|gb|AAA26793|ARO:3003748|oleC	39.0	218	304	325	2.37e-48	163
C55_contig_822_99	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	38.6	210	304	293	4.77e-42	145
C55_contig_822_99	SARG|gb|AAR96051.1|ARO:3002894|otrC	33.3	225	304	351	9.14e-29	112
C55_contig_822_99	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	33.3	225	304	351	2.43e-28	110
C55_contig_822_99	SARG|gb|APB03219.1|ARO:3003986|TaeA	30.1	219	304	648	2.06e-15	75.5
C55_contig_822_99	SARG|gi|738121094|ref|WP_036079133.1|	24.9	197	304	493	3.99e-09	56.2
C55_contig_822_99	SARG|gi|926250866|ref|WP_053589133.1|	22.3	184	304	492	7.13e-08	52.4
C55_contig_822_99	SARG|gi|517611899|ref|WP_018782107.1|	22.5	182	304	492	7.13e-08	52.4
C55_contig_822_129	SARG|ZP_04207693	33.4	296	320	264	9.56e-29	110
C55_contig_822_129	SARG|ZP_03041263	30.8	302	320	267	1.98e-28	109
C55_contig_822_129	SARG|ZP_04202328	33.2	295	320	263	2.53e-28	109
C55_contig_822_129	SARG|ZP_04226949	32.8	296	320	264	5.01e-28	108
C55_contig_822_129	SARG|ZP_04083542	32.1	296	320	263	6.82e-28	108
C55_contig_822_129	SARG|ZP_04070977	32.1	296	320	263	6.82e-28	108
C55_contig_822_129	SARG|ZP_04232797	32.4	296	320	264	6.97e-28	108
C55_contig_822_129	SARG|ZP_04144736	32.8	296	320	263	9.49e-28	107
C55_contig_822_129	SARG|NP_831165	32.1	296	320	263	9.49e-28	107
C55_contig_822_129	SARG|ZP_04113961	33.2	295	320	263	9.49e-28	107
C55_contig_822_159	SARG|gi|445996710|ref|WP_000074565.1|	38.1	215	219	309	4.65e-41	140
C55_contig_822_159	SARG|gi|500448961|gb|EOP61695.1|	36.9	217	219	306	6.66e-40	137
C55_contig_822_159	SARG|gi|500465078|gb|EOP76697.1|	36.9	217	219	306	6.66e-40	137
C55_contig_822_159	SARG|gi|446026113|ref|WP_000103968.1|	36.4	217	219	306	3.66e-39	135
C55_contig_822_159	SARG|gi|445996719|ref|WP_000074574.1|	37.2	215	219	309	3.92e-39	135
C55_contig_822_159	SARG|gi|895736250|emb|COF64653.1|	36.7	215	219	309	7.75e-39	135
C55_contig_822_159	SARG|gi|446110087|ref|WP_000187942.1|	36.7	215	219	309	7.75e-39	135
C55_contig_822_159	SARG|gi|445996714|ref|WP_000074569.1|	36.7	215	219	309	7.75e-39	135
C55_contig_822_159	SARG|gi|445996722|ref|WP_000074577.1|	36.2	213	219	309	7.75e-39	135
C55_contig_822_159	SARG|gi|507044560|ref|WP_016115614.1|	36.2	213	219	306	1.02e-38	134
C55_contig_822_164	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.7	90	128	232	2.79e-19	79.0
C55_contig_822_164	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	47.8	90	128	232	2.79e-19	79.0
C55_contig_822_164	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	47.8	90	128	232	2.79e-19	79.0
C55_contig_822_164	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	47.8	90	128	232	2.79e-19	79.0
C55_contig_822_164	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	47.8	90	128	232	2.79e-19	79.0
C55_contig_822_164	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	41.4	99	128	230	2.04e-18	76.6
C55_contig_822_164	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.7	90	128	232	2.94e-18	76.3
C55_contig_822_164	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.8	93	128	231	7.92e-18	75.1
C55_contig_822_164	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.8	93	128	231	1.55e-17	74.3
C55_contig_822_164	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.8	93	128	231	1.55e-17	74.3
C55_contig_822_167	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.5	218	223	255	2.29e-49	160
C55_contig_822_167	SARG|gi|746253210|ref|WP_039301529.1|	41.0	222	223	648	6.71e-48	165
C55_contig_822_167	SARG|gi|657888313|ref|WP_029592374.1|	40.5	222	223	648	9.29e-48	165
C55_contig_822_167	SARG|gi|495736522|ref|WP_008461101.1|	41.0	222	223	648	1.29e-47	164
C55_contig_822_167	SARG|gi|896325272|ref|WP_049294291.1|	40.1	222	223	648	1.29e-47	164
C55_contig_822_167	SARG|gi|639225329|ref|WP_024561799.1|	40.5	222	223	648	1.78e-47	164
C55_contig_822_167	SARG|gi|746243059|ref|WP_039291473.1|	41.0	222	223	648	1.78e-47	164
C55_contig_822_167	SARG|gi|639218559|ref|WP_024556062.1|	40.5	222	223	648	1.78e-47	164
C55_contig_822_167	SARG|gi|639216333|ref|WP_024554080.1|	40.1	222	223	648	1.78e-47	164
C55_contig_822_167	SARG|Q83LR7	39.2	222	223	648	4.73e-47	163
C55_contig_822_178	SARG|gb|APB03216.1|ARO:3003982|LlmA	58.2	287	288	287	5.61e-135	382
C55_contig_822_179	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.2	239	282	343	2.46e-31	118
C55_contig_822_179	SARG|gi|671541568|ref|WP_031525212.1|	33.6	217	282	648	1.25e-27	110
C55_contig_822_179	SARG|gi|657888313|ref|WP_029592374.1|	33.9	227	282	648	1.06e-26	108
C55_contig_822_179	SARG|gi|639225329|ref|WP_024561799.1|	33.5	227	282	648	4.89e-26	106
C55_contig_822_179	SARG|gi|639218559|ref|WP_024556062.1|	33.5	227	282	648	4.89e-26	106
C55_contig_822_179	SARG|gi|639216333|ref|WP_024554080.1|	33.5	227	282	648	4.89e-26	106
C55_contig_822_179	SARG|gi|746253210|ref|WP_039301529.1|	34.7	216	282	648	2.24e-25	104
C55_contig_822_179	SARG|gi|1001720867|ref|WP_061274204.1|	34.3	216	282	648	4.12e-25	103
C55_contig_822_179	SARG|gi|981224618|ref|WP_059445588.1|	32.4	238	282	646	5.57e-25	103
C55_contig_822_179	SARG|gi|495736522|ref|WP_008461101.1|	34.3	216	282	648	7.56e-25	102
C55_contig_822_180	SARG|ZP_04081918	30.9	288	290	306	1.34e-34	126
C55_contig_822_180	SARG|gi|447195835|ref|WP_001273091.1|	31.0	277	290	306	3.66e-34	125
C55_contig_822_180	SARG|gi|445996710|ref|WP_000074565.1|	32.0	244	290	309	3.90e-34	125
C55_contig_822_180	SARG|gi|445996719|ref|WP_000074574.1|	32.4	225	290	309	5.45e-34	124
C55_contig_822_180	SARG|gi|542061059|gb|ERI11611.1|	28.8	288	290	316	6.29e-34	124
C55_contig_822_180	SARG|gi|447195836|ref|WP_001273092.1|	31.0	277	290	306	7.15e-34	124
C55_contig_822_180	SARG|gi|500194536|ref|WP_011867743.1|	30.6	288	290	306	1.00e-33	124
C55_contig_822_180	SARG|gi|447057509|ref|WP_001134765.1|	32.0	225	290	309	1.06e-33	124
C55_contig_822_180	SARG|gi|488068784|ref|WP_002140181.1|	32.0	225	290	309	1.49e-33	123
C55_contig_822_180	SARG|gi|445996708|ref|WP_000074563.1|	31.1	225	290	309	2.08e-33	123
C55_contig_822_196	SARG|AAN28721	44.1	93	389	108	6.25e-18	77.8
C55_contig_822_203	SARG|gi|803568669|ref|WP_046077412.1|	24.3	206	425	648	4.12e-13	70.1
C55_contig_822_203	SARG|gi|446110352|ref|WP_000188207.1|	24.3	206	425	648	4.12e-13	70.1
C55_contig_822_203	SARG|YP_002382193	24.3	206	425	648	4.12e-13	70.1
C55_contig_822_203	SARG|gi|803575554|ref|WP_046081557.1|	24.3	206	425	648	4.12e-13	70.1
C55_contig_822_203	SARG|gi|446110351|ref|WP_000188206.1|	24.3	206	425	648	4.12e-13	70.1
C55_contig_822_203	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	27.4	208	425	293	1.29e-12	67.0
C55_contig_822_203	SARG|gi|502669352|ref|WP_012905216.1|	23.4	201	425	648	5.25e-12	66.6
C55_contig_822_203	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.4	205	425	351	6.35e-12	65.5
C55_contig_822_203	SARG|gi|736472622|ref|WP_034494292.1|	22.1	213	425	648	3.59e-10	60.8
C55_contig_822_203	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.7	225	425	655	6.33e-10	60.1
C55_contig_822_208	SARG|P45439	31.3	192	285	319	6.40e-14	69.7
C55_contig_822_208	megares|MEG_2845|Drugs|MLS|23S_rRNA_methyltransferases|ERMS_1	31.3	192	285	319	6.40e-14	69.7
C55_contig_822_208	SARG|L22689.1.gene1.p01	33.3	120	285	257	5.08e-12	63.5
C55_contig_822_227	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	28.3	191	249	343	5.69e-19	83.6
C55_contig_822_227	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.4	191	249	307	6.96e-18	80.1
C55_contig_822_282	SARG|gb|WP_082039181.1|ARO:3007028|salD	28.1	185	268	544	5.23e-08	52.4
C55_contig_822_346	SARG|gi|542061059|gb|ERI11611.1|	35.7	221	293	316	4.86e-34	125
C55_contig_822_346	SARG|gi|445996722|ref|WP_000074577.1|	34.0	238	293	309	1.15e-33	124
C55_contig_822_346	SARG|gi|445996723|ref|WP_000074578.1|	33.6	238	293	309	1.60e-33	123
C55_contig_822_346	SARG|gi|884875933|emb|CKG93789.1|	33.6	238	293	309	2.24e-33	123
C55_contig_822_346	SARG|gi|445996724|ref|WP_000074579.1|	33.6	238	293	309	3.13e-33	122
C55_contig_822_346	SARG|gi|445996729|ref|WP_000074584.1|	33.3	234	293	309	4.37e-33	122
C55_contig_822_346	SARG|gi|1043490477|ref|WP_065382463.1|	33.2	238	293	309	4.37e-33	122
C55_contig_822_346	SARG|gi|445996726|ref|WP_000074581.1|	33.2	238	293	309	4.37e-33	122
C55_contig_822_346	SARG|gi|507054395|ref|WP_016125339.1|	33.2	238	293	309	4.37e-33	122
C55_contig_822_346	SARG|gi|445996732|ref|WP_000074587.1|	34.4	221	293	309	6.10e-33	122
C55_contig_822_366	SARG|DQ212986.1.gene3.p01	48.6	70	72	75	1.64e-20	75.9
C55_contig_822_419	SARG|gi|639209604|ref|WP_024547784.1|	37.6	221	247	648	1.93e-39	143
C55_contig_822_419	SARG|Q83LR7	37.3	220	247	648	5.02e-39	142
C55_contig_822_419	SARG|gi|647325472|ref|WP_025760953.1|	37.3	220	247	648	5.02e-39	142
C55_contig_822_419	SARG|gi|647323678|ref|WP_025760497.1|	37.3	220	247	648	5.02e-39	142
C55_contig_822_419	SARG|gi|446110311|ref|WP_000188166.1|	36.8	220	247	648	6.91e-39	141
C55_contig_822_419	SARG|gi|1033064422|ref|WP_064375412.1|	37.7	223	247	648	6.91e-39	141
C55_contig_822_419	SARG|YP_403947	36.8	220	247	650	6.99e-39	141
C55_contig_822_419	SARG|gi|446110301|ref|WP_000188156.1|	36.8	220	247	648	1.30e-38	140
C55_contig_822_419	SARG|gi|1035735809|ref|WP_064572349.1|	36.8	220	247	648	1.79e-38	140
C55_contig_822_419	SARG|gi|974633183|ref|WP_059219858.1|	36.8	220	247	648	1.79e-38	140
C55_contig_822_427	SARG|gi|505177635|ref|WP_015364737.1|	26.8	418	461	451	5.67e-34	131
C55_contig_822_427	SARG|gi|686155635|ref|WP_031787393.1|	27.4	419	461	451	5.16e-33	129
C55_contig_822_427	SARG|gi|446573718|ref|WP_000651064.1|	27.2	423	461	451	5.16e-33	129
C55_contig_822_427	SARG|ZP_04679156	25.8	418	461	451	3.40e-32	126
C55_contig_822_427	SARG|gi|488374619|ref|WP_002444004.1|	27.0	422	461	452	3.44e-32	126
C55_contig_822_427	SARG|gi|537465183|ref|WP_020976941.1|	27.0	418	461	451	4.65e-32	126
C55_contig_822_427	SARG|gi|565830932|ref|WP_023914633.1|	27.0	418	461	451	6.36e-32	125
C55_contig_822_427	SARG|gi|1006223553|ref|WP_061745579.1|	27.0	418	461	451	6.36e-32	125
C55_contig_822_427	SARG|gi|446573690|ref|WP_000651036.1|	27.0	418	461	451	8.70e-32	125
C55_contig_822_427	SARG|gi|446573707|ref|WP_000651053.1|	27.0	418	461	451	1.19e-31	125
C55_contig_822_459	SARG|gi|498467693|ref|WP_010773049.1|	27.1	351	332	700	8.13e-12	65.1
C55_contig_822_459	SARG|FJ872411.1.gene43.p01	26.8	310	332	702	6.09e-10	59.3
C55_contig_822_459	SARG|AAY67970	26.2	317	332	698	1.06e-08	55.5
C55_contig_822_459	SARG|AF162694.1.gene4.p01	26.1	314	332	698	1.87e-08	54.7
C55_contig_822_459	SARG|gi|657686198|ref|WP_029487032.1|	26.1	314	332	698	2.49e-08	54.3
C55_contig_822_459	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	23.3	347	332	712	4.42e-08	53.5
C55_contig_822_459	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	23.3	317	332	700	9.94e-07	49.3
C55_contig_822_459	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	23.8	315	332	700	1.75e-06	48.5
C55_contig_822_459	SARG|gb|ABA71733.1|ARO:3002972|vanTG	24.7	344	332	712	1.76e-06	48.5
C55_contig_822_507	SARG|L20800.gene.p01	28.9	454	529	652	5.64e-37	144
C55_contig_822_507	SARG|NP_348076	28.4	451	529	652	1.03e-36	143
C55_contig_822_507	SARG|YP_002850805	28.9	453	529	652	2.56e-36	142
C55_contig_822_507	SARG|ZP_02952732	28.6	454	529	652	2.56e-36	142
C55_contig_822_507	SARG|ZP_02632674	28.6	454	529	660	2.69e-36	142
C55_contig_822_507	SARG|Q08425	29.1	454	529	641	1.64e-34	136
C55_contig_822_507	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	29.1	454	529	657	1.79e-34	136
C55_contig_822_507	SARG|Z21523.gene.p01	29.1	454	529	657	1.79e-34	136
C55_contig_822_507	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	28.9	454	529	654	5.83e-34	135
C55_contig_822_507	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	28.9	454	529	670	6.30e-34	135
C55_contig_822_517	SARG|gb|MBW0770001.1|ARO:3007026|salB	21.4	501	888	541	1.93e-21	98.2
C55_contig_822_517	SARG|U82085.gene.p01	24.9	547	888	552	3.24e-19	91.3
C55_contig_822_517	SARG|gb|ABX00624.1|ARO:3002881|lmrC	26.6	557	888	550	2.15e-17	85.5
C55_contig_822_517	SARG|gb|WP_096809342.1|ARO:3007029|salE	28.4	183	888	543	2.96e-14	75.5
C55_contig_822_517	SARG|gi|445996724|ref|WP_000074579.1|	28.8	212	888	309	1.36e-13	71.6
C55_contig_822_517	SARG|gi|1043490477|ref|WP_065382463.1|	28.8	212	888	309	1.36e-13	71.6
C55_contig_822_517	SARG|gi|445996726|ref|WP_000074581.1|	28.8	212	888	309	1.36e-13	71.6
C55_contig_822_517	SARG|gi|447057509|ref|WP_001134765.1|	28.3	212	888	309	1.36e-13	71.6
C55_contig_822_517	SARG|gi|445996723|ref|WP_000074578.1|	28.8	212	888	309	1.36e-13	71.6
C55_contig_822_517	SARG|gi|507054395|ref|WP_016125339.1|	28.8	212	888	309	1.36e-13	71.6
C55_contig_822_523	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	25.2	230	328	346	1.43e-11	63.5
C55_contig_822_544	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.3	866	922	1024	2.91e-125	403
C55_contig_822_544	SARG|gb|CAA53189|ARO:3000521|mupA	30.3	866	922	1024	2.91e-125	403
C55_contig_822_544	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	30.3	866	922	1024	4.06e-125	402
C55_contig_822_544	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.3	866	922	1024	4.06e-125	402
C55_contig_822_544	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	29.2	889	922	1033	4.06e-113	370
C55_contig_822_544	SARG|gb|AEY83581|ARO:3000510|mupB	29.2	889	922	1033	4.06e-113	370
C55_contig_822_561	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.2	867	804	1024	6.08e-32	132
C55_contig_822_561	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.2	867	804	1024	6.08e-32	132
C55_contig_822_561	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.2	867	804	1024	6.08e-32	132
C55_contig_822_561	SARG|gb|CAA53189|ARO:3000521|mupA	23.2	867	804	1024	6.08e-32	132
C55_contig_822_561	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	21.5	840	804	1033	4.44e-28	120
C55_contig_822_561	SARG|gb|AEY83581|ARO:3000510|mupB	21.5	840	804	1033	4.44e-28	120
C55_contig_822_561	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.7	699	804	1107	1.42e-14	77.0
C55_contig_822_561	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.7	699	804	1107	1.42e-14	77.0
C55_contig_822_590	SARG|gb|AAC75314.1|ARO:3003578|pmrF	28.5	316	318	322	1.33e-35	130
C55_contig_822_622	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.9	594	702	718	5.79e-88	290
C55_contig_822_627	SARG|gi|851935911|ref|WP_048224705.1|	31.8	308	306	660	4.15e-42	152
C55_contig_822_627	SARG|gi|851917461|ref|WP_048217311.1|	31.8	308	306	660	5.71e-42	152
C55_contig_822_627	SARG|gi|489117806|ref|WP_003027650.1|	31.8	308	306	660	5.71e-42	152
C55_contig_822_627	SARG|gi|765458296|ref|WP_044714032.1|	31.8	308	306	660	5.71e-42	152
C55_contig_822_627	SARG|gi|696375142|ref|WP_032949690.1|	31.8	308	306	660	5.71e-42	152
C55_contig_822_627	SARG|gi|507079934|ref|WP_016150692.1|	31.5	308	306	660	2.04e-41	150
C55_contig_822_627	SARG|gi|757799830|ref|WP_043017032.1|	31.8	308	306	660	2.80e-41	150
C55_contig_822_627	SARG|gi|507086291|ref|WP_016157032.1|	32.5	308	306	660	3.85e-41	150
C55_contig_822_627	SARG|gi|489931383|ref|WP_003834702.1|	31.8	308	306	660	3.85e-41	150
C55_contig_822_627	SARG|gi|1002399350|ref|WP_061382108.1|	31.8	308	306	660	5.29e-41	149
C55_contig_822_659	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.1	210	381	364	3.26e-21	92.8
C55_contig_822_659	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.1	210	381	364	3.26e-21	92.8
C55_contig_822_659	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.7	304	381	361	2.30e-19	87.4
C55_contig_822_659	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	24.8	206	381	364	5.41e-17	80.5
C55_contig_822_659	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	24.8	206	381	364	5.41e-17	80.5
C55_contig_822_660	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	39.3	201	226	233	2.44e-47	155
C55_contig_822_660	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	39.3	201	226	231	2.06e-45	150
C55_contig_822_660	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.2	219	226	219	7.32e-40	135
C55_contig_822_660	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	219	1.62e-38	132
C55_contig_822_660	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	219	2.29e-38	131
C55_contig_822_660	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	220	2.35e-38	131
C55_contig_822_660	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	220	3.31e-38	131
C55_contig_822_660	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	222	226	220	3.31e-38	131
C55_contig_822_660	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	38.5	200	226	225	2.11e-37	129
C55_contig_822_660	SARG|ZP_02848503	34.2	225	226	221	6.49e-35	122
C55_contig_822_685	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	30.0	686	662	703	3.69e-81	270
C55_contig_822_709	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.3	227	441	451	1.40e-22	98.6
C55_contig_822_709	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.9	215	441	367	3.34e-21	93.6
C55_contig_822_709	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.9	215	441	368	3.38e-21	93.6
C55_contig_822_710	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	230	236	231	4.51e-44	147
C55_contig_822_710	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.0	230	236	231	1.27e-43	145
C55_contig_822_710	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.4	231	236	232	1.84e-43	145
C55_contig_822_710	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.9	231	236	232	5.17e-43	144
C55_contig_822_710	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.8	233	236	231	1.00e-42	143
C55_contig_822_710	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.1	230	236	239	2.48e-42	142
C55_contig_822_710	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.4	231	236	233	5.93e-42	141
C55_contig_822_710	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.1	230	236	231	4.43e-41	139
C55_contig_822_710	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.8	229	236	231	4.43e-41	139
C55_contig_822_710	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.0	236	236	235	1.95e-40	137
C55_contig_822_714	SARG|gb|AAK76136.1|ARO:3000025|patB	32.3	609	633	588	1.79e-100	317
C55_contig_822_714	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.5	550	633	664	4.51e-95	305
C55_contig_822_714	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.7	618	633	579	9.29e-87	281
C55_contig_822_714	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.9	619	633	579	2.69e-85	277
C55_contig_822_714	SARG|gi|497748188|ref|WP_010062372.1|	30.7	605	633	605	3.98e-83	272
C55_contig_822_714	SARG|gi|695887424|ref|WP_032788534.1|	30.7	602	633	605	1.52e-82	270
C55_contig_822_714	SARG|gi|664180077|ref|WP_030714054.1|	30.6	602	633	605	2.97e-82	270
C55_contig_822_714	SARG|gi|948137056|ref|WP_056795395.1|	30.9	609	633	602	3.87e-82	269
C55_contig_822_714	SARG|gi|664170108|ref|WP_030704355.1|	30.6	634	633	603	5.54e-82	269
C55_contig_822_714	SARG|gi|951183771|ref|WP_057661487.1|	30.9	605	633	603	1.08e-81	268
C55_contig_822_715	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.5	552	583	575	9.34e-104	323
C55_contig_822_715	SARG|gb|AAK76137.1|ARO:3000024|patA	34.5	522	583	564	4.53e-101	316
C55_contig_822_715	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.3	485	583	664	5.96e-68	231
C55_contig_822_715	SARG|gb|AAK76136.1|ARO:3000025|patB	30.4	483	583	588	9.77e-68	229
C55_contig_822_715	SARG|gb|CDO61516.1|ARO:3003949|efrB	37.0	332	583	362	1.92e-63	211
C55_contig_822_715	SARG|gi|1045390184|ref|WP_065479071.1|	28.8	535	583	605	1.31e-58	205
C55_contig_822_715	SARG|gi|944470764|ref|WP_055701183.1|	42.6	270	583	601	2.33e-58	204
C55_contig_822_715	SARG|gi|695865802|ref|WP_032778631.1|	41.6	269	583	605	3.46e-58	204
C55_contig_822_715	SARG|gi|497748188|ref|WP_010062372.1|	41.3	269	583	605	1.27e-57	202
C55_contig_822_715	SARG|gi|764446018|ref|WP_044369325.1|	41.3	269	583	605	1.27e-57	202
C55_contig_822_729	SARG|AAZ79478	36.6	183	607	657	6.47e-28	117
C55_contig_822_729	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	36.6	183	607	657	6.47e-28	117
C55_contig_822_729	SARG|Z21523.gene.p01	36.6	183	607	657	6.47e-28	117
C55_contig_822_729	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	36.6	183	607	670	6.75e-28	117
C55_contig_822_729	SARG|AAB51122	36.6	183	607	670	6.75e-28	117
C55_contig_822_729	SARG|Q08425	37.2	180	607	641	1.09e-27	117
C55_contig_822_729	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	37.2	180	607	641	1.09e-27	117
C55_contig_822_729	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	37.2	180	607	654	1.14e-27	117
C55_contig_822_729	SARG|BAD46890	36.1	183	607	657	1.15e-27	117
C55_contig_822_729	SARG|Q52360	36.7	180	607	641	1.93e-27	116
C55_contig_822_748	SARG|gi|505177635|ref|WP_015364737.1|	24.7	438	466	451	3.33e-39	146
C55_contig_822_748	SARG|ZP_04679156	25.3	438	466	451	2.29e-38	144
C55_contig_822_748	SARG|gi|686432388|ref|WP_031921070.1|	24.4	434	466	451	1.57e-37	141
C55_contig_822_748	SARG|ZP_03986195	24.2	434	466	451	2.98e-37	140
C55_contig_822_748	SARG|gi|446573695|ref|WP_000651041.1|	24.2	434	466	451	4.10e-37	140
C55_contig_822_748	SARG|gi|686448604|ref|WP_031928572.1|	24.0	434	466	451	4.10e-37	140
C55_contig_822_748	SARG|gi|446573690|ref|WP_000651036.1|	24.0	434	466	451	5.64e-37	140
C55_contig_822_748	SARG|gi|1006223553|ref|WP_061745579.1|	24.2	430	466	451	1.07e-36	139
C55_contig_822_748	SARG|gi|686408548|ref|WP_031913080.1|	24.0	434	466	451	1.47e-36	139
C55_contig_822_748	SARG|gi|516415429|ref|WP_017804827.1|	24.0	434	466	451	1.47e-36	139
C55_contig_822_752	SARG|gi|1035706844|ref|WP_064548272.1|	37.7	77	940	648	1.20e-08	57.8
C55_contig_822_807	megares|MEG_7331|Drugs|Glycopeptide|VanA-type_resistance_protein|VAN_1	59.6	47	319	114	3.31e-10	55.8
C55_contig_822_807	CARD|gb|AAO82019.1|ARO:3004254|vanV_in_vanB_cl	59.6	47	319	114	3.31e-10	55.8
C55_contig_822_828	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.6	221	266	547	1.38e-11	63.2
C55_contig_822_828	SARG|gb|AEA37904.1|ARO:3003112|lsaC	39.2	74	266	492	4.73e-09	55.5
C55_contig_822_855	SARG|gb|CAH14033.1|ARO:3004100|LpeB	26.3	835	1346	1014	2.83e-55	209
C55_contig_822_855	SARG|gb|AAG05914|ARO:3004075|MuxC	24.9	830	1346	1036	7.44e-55	207
C55_contig_822_855	CARD|gb|AAC75137.1|ARO:3000794|mdtC	26.4	853	1346	1025	4.77e-53	202
C55_contig_822_855	ResF|tmexD4_1_CP091084_1	24.5	845	1346	1044	2.28e-49	190
C55_contig_822_855	NCBI|WP_027591160.1|1|1|tmexD2|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD2|AMR|tetracycline	24.3	845	1346	1044	1.60e-48	187
C55_contig_822_855	CARD|gb|AAG07594.1|ARO:3000808|MexI	24.7	811	1346	1029	6.11e-48	186
C55_contig_822_855	ResF|tmexD3_1_LC633285_1	24.1	846	1346	1044	1.12e-47	185
C55_contig_822_855	NCBI|WP_034065037.1|1|1|tmexD3|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD3|AMR|tetracycline	24.1	846	1346	1044	1.12e-47	185
C55_contig_822_855	NCBI|WP_118842627.1|1|1|tmexD1|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD1|AMR|tetracycline	24.0	846	1346	1044	2.59e-47	184
C55_contig_822_855	SARG|YP_348488	24.6	846	1346	1043	7.83e-47	182
C55_contig_822_893	SARG|L42544.gene.p01	32.1	635	870	651	5.22e-97	316
C55_contig_822_893	SARG|AAV80410	32.0	635	870	651	5.22e-97	316
C55_contig_822_893	SARG|YP_002850805	31.9	623	870	652	4.30e-91	300
C55_contig_822_893	SARG|ZP_02952732	31.7	621	870	652	5.99e-91	300
C55_contig_822_893	SARG|ZP_02632674	31.7	621	870	660	7.26e-91	300
C55_contig_822_893	SARG|L20800.gene.p01	31.7	621	870	652	1.16e-90	299
C55_contig_822_893	SARG|NP_348076	31.1	623	870	652	2.28e-88	293
C55_contig_822_893	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.8	614	870	641	2.44e-87	290
C55_contig_822_893	SARG|AAZ79478	29.8	614	870	657	3.57e-87	290
C55_contig_822_893	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.0	614	870	654	6.42e-87	289
C55_contig_822_913	SARG|gi|686432388|ref|WP_031921070.1|	22.4	434	587	451	1.19e-18	87.8
C55_contig_822_913	SARG|gi|1006223553|ref|WP_061745579.1|	22.1	434	587	451	1.19e-18	87.8
C55_contig_822_913	SARG|gi|686304329|ref|WP_031867798.1|	22.4	434	587	451	1.19e-18	87.8
C55_contig_822_913	SARG|ZP_04679156	22.4	434	587	451	1.59e-18	87.4
C55_contig_822_913	SARG|ZP_03986195	22.4	434	587	451	1.59e-18	87.4
C55_contig_822_913	SARG|gi|446573695|ref|WP_000651041.1|	22.4	434	587	451	1.59e-18	87.4
C55_contig_822_913	SARG|gi|446573707|ref|WP_000651053.1|	22.7	436	587	451	2.12e-18	87.0
C55_contig_822_913	SARG|gi|505177635|ref|WP_015364737.1|	23.8	433	587	451	2.12e-18	87.0
C55_contig_822_913	SARG|gi|537465183|ref|WP_020976941.1|	22.7	436	587	451	3.76e-18	86.3
C55_contig_822_913	SARG|gi|686408548|ref|WP_031913080.1|	22.1	434	587	451	3.76e-18	86.3
C55_contig_822_941	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.6	219	353	255	1.51e-38	137
C55_contig_822_941	SARG|gb|AAC75271.1|ARO:3003952|yojI	31.2	215	353	547	4.20e-18	84.3
C55_contig_822_941	SARG|gb|APB03219.1|ARO:3003986|TaeA	27.0	233	353	648	2.06e-17	82.4
C55_contig_822_941	SARG|M80346.gene.p01	29.9	184	353	551	3.65e-10	60.1
C55_contig_822_941	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	29.9	184	353	551	3.65e-10	60.1
C55_contig_822_985	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	45.3	159	162	159	6.72e-43	139
C55_contig_822_1000	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.4	247	375	355	2.48e-26	107
C55_contig_822_1000	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.4	247	375	355	2.48e-26	107
C55_contig_822_1000	SARG|ACM47285	32.4	247	375	363	2.78e-26	107
C55_contig_822_1000	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.1	251	375	355	5.91e-25	103
C55_contig_822_1000	SARG|BAE96115	31.1	251	375	355	5.91e-25	103
C55_contig_822_1000	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.0	258	375	356	7.44e-24	100
C55_contig_822_1000	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.2	247	375	356	1.91e-23	99.0
C55_contig_822_1000	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	30.5	203	375	209	2.17e-20	87.4
C55_contig_822_1014	SARG|gb|AAB53445.1|ARO:3002897|SAT-4	32.3	93	145	180	1.33e-06	44.7
C55_contig_822_1014	megares|MEG_6169|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	32.3	93	145	180	1.33e-06	44.7
C55_contig_822_1014	NCBI|WP_000627290.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	32.3	93	145	180	1.33e-06	44.7
C55_contig_822_1014	megares|MEG_6166|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	32.3	93	145	180	1.33e-06	44.7
C55_contig_822_1014	NCBI|WP_063854935.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	32.3	93	145	180	1.83e-06	44.3
C55_contig_822_1014	megares|MEG_6165|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	32.3	93	145	180	1.83e-06	44.3
C55_contig_822_1017	SARG|gb|ABA71733.1|ARO:3002972|vanTG	39.0	374	393	712	1.01e-82	266
C55_contig_822_1017	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	38.5	374	393	712	1.74e-78	254
C55_contig_822_1017	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	35.3	374	393	711	9.15e-67	223
C55_contig_822_1023	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.6	223	218	231	1.39e-49	160
C55_contig_822_1023	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.3	223	218	232	4.56e-48	156
C55_contig_822_1023	SARG|ZP_02848503	38.6	215	218	221	1.07e-43	145
C55_contig_822_1023	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	218	235	3.15e-43	144
C55_contig_822_1023	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.6	223	218	231	1.12e-42	142
C55_contig_822_1023	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	223	218	231	1.12e-42	142
C55_contig_822_1023	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.0	227	218	229	1.50e-42	142
C55_contig_822_1023	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.7	226	218	230	2.18e-42	142
C55_contig_822_1023	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	223	218	231	2.24e-42	142
C55_contig_822_1023	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	223	218	231	2.24e-42	142
C55_contig_822_1024	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.0	326	479	451	9.81e-31	122
C55_contig_822_1024	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.6	261	479	370	1.74e-24	103
C55_contig_822_1024	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.6	286	479	365	7.50e-24	101
C55_contig_822_1024	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	28.7	327	479	364	1.36e-23	100
C55_contig_822_1024	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	28.7	327	479	364	1.36e-23	100
C55_contig_822_1024	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.5	331	479	368	1.20e-22	98.2
C55_contig_822_1024	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.9	266	479	367	2.94e-22	97.1
C55_contig_822_1024	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.5	323	479	386	4.91e-22	96.7
C55_contig_822_1024	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	28.5	323	479	386	4.91e-22	96.7
C55_contig_822_1024	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.4	331	479	386	1.63e-21	95.1
C55_contig_822_1041	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	31.1	434	418	444	5.17e-54	184
C55_contig_822_1091	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.0	230	236	231	5.48e-54	172
C55_contig_822_1091	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.9	228	236	232	1.02e-51	166
C55_contig_822_1091	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.9	228	236	232	1.02e-51	166
C55_contig_822_1091	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.7	229	236	232	1.84e-49	160
C55_contig_822_1091	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	236	231	1.43e-48	158
C55_contig_822_1091	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.0	229	236	229	1.90e-48	158
C55_contig_822_1091	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	236	231	2.85e-48	157
C55_contig_822_1091	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.9	232	236	235	4.51e-48	157
C55_contig_822_1091	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.2	228	236	231	5.69e-48	157
C55_contig_822_1091	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	236	231	3.20e-47	155
C55_contig_822_1092	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.2	313	480	451	5.04e-25	106
C55_contig_822_1092	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.0	221	480	359	4.07e-21	93.6
C55_contig_822_1092	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	25.0	228	480	380	4.12e-20	90.9
C55_contig_822_1092	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	228	480	380	4.12e-20	90.9
C55_contig_822_1119	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.8	575	580	575	2.29e-121	369
C55_contig_822_1119	SARG|gb|AAK76137.1|ARO:3000024|patA	34.1	543	580	564	2.89e-93	296
C55_contig_822_1119	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.1	569	580	582	2.17e-67	228
C55_contig_822_1119	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.8	580	580	579	4.06e-65	222
C55_contig_822_1119	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.1	592	580	579	5.65e-65	221
C55_contig_822_1119	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.9	551	580	574	6.12e-54	191
C55_contig_822_1119	SARG|gi|739906046|ref|WP_037756452.1|	27.3	550	580	620	6.04e-52	187
C55_contig_822_1119	SARG|gi|860594225|ref|WP_048475168.1|	26.7	573	580	620	6.04e-52	187
C55_contig_822_1119	SARG|gi|948137056|ref|WP_056795395.1|	27.5	561	580	602	6.35e-52	186
C55_contig_822_1119	SARG|gi|917229923|ref|WP_051836635.1|	27.3	539	580	620	1.14e-51	186
C55_contig_822_1120	SARG|gb|AAK76136.1|ARO:3000025|patB	34.0	577	583	588	5.16e-107	332
C55_contig_822_1120	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.4	497	583	664	1.27e-103	326
C55_contig_822_1120	SARG|gi|860594225|ref|WP_048475168.1|	34.1	504	583	620	7.61e-96	304
C55_contig_822_1120	SARG|gi|926376632|ref|WP_053705806.1|	34.3	504	583	620	2.26e-94	300
C55_contig_822_1120	SARG|gi|1045390184|ref|WP_065479071.1|	32.1	580	583	605	3.05e-94	300
C55_contig_822_1120	SARG|gi|663330365|ref|WP_030329892.1|	32.6	583	583	607	4.50e-94	299
C55_contig_822_1120	SARG|gi|917155568|ref|WP_051762280.1|	33.7	504	583	620	1.73e-93	298
C55_contig_822_1120	SARG|gi|759527374|ref|WP_043247487.1|	32.4	583	583	605	2.33e-93	297
C55_contig_822_1120	SARG|gi|799286378|ref|WP_045936958.1|	33.9	504	583	620	2.42e-93	298
C55_contig_822_1120	SARG|gi|917127754|ref|WP_051734466.1|	33.9	504	583	620	2.42e-93	298
C55_contig_822_1123	SARG|AJ514254.gene.p01	22.3	676	691	640	2.01e-47	176
C55_contig_822_1123	SARG|ABI81214	25.0	657	691	639	1.70e-44	168
C55_contig_822_1123	SARG|X04388.gene.p01	24.7	657	691	639	3.13e-44	167
C55_contig_822_1123	SARG|YP_002738300	24.8	657	691	639	5.77e-44	166
C55_contig_822_1123	SARG|ABB70054	24.8	657	691	639	1.44e-43	165
C55_contig_822_1123	SARG|BAB71968	24.2	657	691	639	4.84e-43	164
C55_contig_822_1123	SARG|gi|319894056|gb|ADV76307.1|	24.4	660	691	639	2.20e-42	162
C55_contig_822_1123	SARG|AM180355.1.gene636.p01	23.7	659	691	639	7.38e-42	160
C55_contig_822_1123	SARG|FN594949.1.gene24.p01	22.3	656	691	640	1.51e-40	156
C55_contig_822_1171	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.2	234	208	648	9.42e-21	88.6
C55_contig_822_1171	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	26.2	191	208	504	3.50e-12	63.5
C55_contig_822_1171	SARG|M80346.gene.p01	35.3	156	208	551	5.46e-11	60.1
C55_contig_822_1171	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	35.3	156	208	551	5.46e-11	60.1
C55_contig_822_1171	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	37.3	75	208	550	1.22e-08	53.1
C55_contig_822_1171	SARG|gi|488338532|ref|WP_002407917.1|	23.2	142	208	498	1.04e-06	47.4
C55_contig_822_1171	SARG|gb|MBW0764195.1|ARO:3007027|salC	22.0	200	208	541	2.60e-06	46.2
C55_contig_822_1186	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.0	831	898	1033	7.14e-78	273
C55_contig_822_1186	SARG|gb|AEY83581|ARO:3000510|mupB	25.0	831	898	1033	7.14e-78	273
C55_contig_822_1186	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.0	835	898	1024	1.28e-67	243
C55_contig_822_1186	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.8	825	898	1024	1.73e-67	243
C55_contig_822_1186	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.0	835	898	1024	4.30e-67	241
C55_contig_822_1186	SARG|gb|CAA53189|ARO:3000521|mupA	24.8	825	898	1024	5.82e-67	241
C55_contig_822_1186	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	25.0	480	898	1107	8.47e-34	139
C55_contig_822_1186	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	25.0	480	898	1107	8.47e-34	139
C55_contig_822_1268	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	36.9	130	401	639	6.34e-16	78.6
C55_contig_822_1269	SARG|L42544.gene.p01	26.8	678	700	651	1.14e-74	252
C55_contig_822_1269	SARG|AAV80410	26.8	678	700	651	2.20e-74	251
C55_contig_822_1269	SARG|NP_348076	27.1	687	700	652	3.09e-72	246
C55_contig_822_1269	SARG|YP_002850805	27.3	684	700	652	5.94e-72	245
C55_contig_822_1269	SARG|ABN80187	27.3	673	700	640	4.55e-70	239
C55_contig_822_1269	SARG|ZP_02952732	26.9	685	700	652	1.11e-69	239
C55_contig_822_1269	SARG|ZP_02632674	26.9	685	700	660	1.29e-69	239
C55_contig_822_1269	SARG|ACI02041	27.3	673	700	639	2.28e-69	238
C55_contig_822_1269	SARG|DQ294299.gene.p01	27.3	673	700	639	2.28e-69	238
C55_contig_822_1269	SARG|L20800.gene.p01	26.9	685	700	652	2.95e-69	238
C55_contig_822_1282	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	39.1	128	568	373	2.52e-19	89.0
C55_contig_822_1295	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.5	255	649	1033	3.19e-10	62.4
C55_contig_822_1295	SARG|gb|AEY83581|ARO:3000510|mupB	25.5	255	649	1033	3.19e-10	62.4
C55_contig_822_1328	SARG|gb|CAE00499.1|ARO:3003835|cdeA	39.8	425	455	441	8.11e-100	305
C55_contig_822_1329	SARG|AAD42183	32.1	137	385	322	1.39e-11	63.9
C55_contig_822_1329	SARG|AAR37059	29.4	136	385	323	1.40e-11	63.9
C55_contig_822_1329	SARG|AAD41881	30.9	136	385	323	1.88e-11	63.5
C55_contig_822_1329	SARG|AY082011.1.gene6.p01	27.4	237	385	323	1.88e-11	63.5
C55_contig_822_1329	SARG|gi|552942232|ref|WP_023043160.1|	27.4	237	385	323	3.37e-11	62.8
C55_contig_822_1329	SARG|AAD51059	30.9	136	385	323	3.37e-11	62.8
C55_contig_822_1343	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	27.3	362	395	712	8.59e-32	126
C55_contig_822_1371	ResF|mre(A)_1_U92073_1	33.9	283	311	310	2.72e-39	139
C55_contig_822_1371	SARG|gb|AAB64408.1|ARO:3007050|mreA	33.9	283	311	311	2.78e-39	139
C55_contig_822_1376	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	629	5.58e-30	124
C55_contig_822_1376	ResF|tet(O/W)_3_AM889120_1	28.5	435	604	639	5.84e-30	124
C55_contig_822_1376	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	629	1.33e-29	122
C55_contig_822_1376	ResF|tet(O/W)_4_AM889121_1	28.5	435	604	639	1.39e-29	122
C55_contig_822_1376	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.3	435	604	629	2.38e-29	122
C55_contig_822_1376	ResF|tet(O/W)_1_AM889118_1	28.3	435	604	639	2.49e-29	122
C55_contig_822_1376	SARG|AAO42740	28.5	435	604	639	3.32e-29	121
C55_contig_822_1376	SARG|AY485126.gene.p01	28.5	435	604	639	3.32e-29	121
C55_contig_822_1376	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	639	3.32e-29	121
C55_contig_822_1376	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	629	4.25e-29	121
C55_contig_822_1389	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	36.7	109	283	308	2.29e-14	70.9
C55_contig_822_1407	SARG|gi|447195835|ref|WP_001273091.1|	39.7	219	319	306	1.60e-48	163
C55_contig_822_1407	SARG|gi|447195836|ref|WP_001273092.1|	39.3	219	319	306	4.45e-48	162
C55_contig_822_1407	SARG|gi|445996719|ref|WP_000074574.1|	38.8	219	319	309	9.50e-48	161
C55_contig_822_1407	SARG|ZP_04081918	38.8	219	319	306	2.44e-47	160
C55_contig_822_1407	SARG|gi|445996723|ref|WP_000074578.1|	38.8	219	319	309	5.21e-47	159
C55_contig_822_1407	SARG|gi|445996710|ref|WP_000074565.1|	37.9	219	319	309	7.33e-47	159
C55_contig_822_1407	SARG|gi|445996722|ref|WP_000074577.1|	38.4	219	319	309	7.33e-47	159
C55_contig_822_1407	SARG|gi|1043490477|ref|WP_065382463.1|	38.4	219	319	309	1.45e-46	158
C55_contig_822_1407	SARG|gi|445996726|ref|WP_000074581.1|	38.4	219	319	309	1.45e-46	158
C55_contig_822_1407	SARG|gi|884875933|emb|CKG93789.1|	37.9	219	319	309	1.45e-46	158
C55_contig_822_1411	SARG|gb|AAC75314.1|ARO:3003578|pmrF	30.4	309	325	322	1.09e-36	133
C55_contig_822_1439	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.9	677	692	703	1.06e-161	481
C55_contig_822_1450	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	28.6	479	674	633	4.50e-46	172
C55_contig_822_1463	SARG|gb|MBY8651253.1|ARO:3007189|vanP	31.2	356	356	342	6.31e-38	137
C55_contig_822_1464	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.5	456	451	481	2.28e-96	297
C55_contig_822_1464	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.4	452	451	451	1.32e-93	289
C55_contig_822_1464	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	36.6	451	451	451	1.47e-92	286
C55_contig_822_1476	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.8	340	524	451	2.18e-32	128
C55_contig_822_1476	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.1	288	524	370	1.13e-29	119
C55_contig_822_1476	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.6	248	524	381	1.35e-29	119
C55_contig_822_1476	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.6	248	524	381	1.35e-29	119
C55_contig_822_1476	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.2	242	524	367	1.47e-29	118
C55_contig_822_1476	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.2	242	524	368	1.49e-29	118
C55_contig_822_1476	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	248	524	381	3.41e-29	117
C55_contig_822_1476	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	248	524	381	3.41e-29	117
C55_contig_822_1476	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.6	250	524	381	8.63e-29	116
C55_contig_822_1476	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.6	250	524	381	8.63e-29	116
C55_contig_822_1477	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.2	225	228	231	1.48e-54	173
C55_contig_822_1477	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.4	229	228	232	4.31e-54	172
C55_contig_822_1477	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.4	229	228	232	4.31e-54	172
C55_contig_822_1477	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.7	224	228	219	1.17e-53	171
C55_contig_822_1477	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.3	226	228	232	7.82e-52	166
C55_contig_822_1477	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.1	228	228	229	1.01e-51	166
C55_contig_822_1477	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.0	227	228	231	4.86e-50	162
C55_contig_822_1477	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	228	235	1.54e-49	160
C55_contig_822_1477	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	228	231	5.48e-49	159
C55_contig_822_1477	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	228	231	7.75e-49	159
C55_contig_822_1494	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	44.3	219	243	343	1.10e-55	180
C55_contig_822_1494	SARG|gb|AAA26793|ARO:3003748|oleC	40.8	218	243	325	5.56e-48	160
C55_contig_822_1494	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	40.8	218	243	325	5.56e-48	160
C55_contig_822_1494	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	37.4	230	243	293	1.34e-40	140
C55_contig_822_1494	SARG|gi|500465078|gb|EOP76697.1|	39.3	219	243	306	1.08e-38	135
C55_contig_822_1494	SARG|gi|500448961|gb|EOP61695.1|	39.3	219	243	306	1.52e-38	135
C55_contig_822_1494	SARG|gi|488120365|ref|WP_002191762.1|	38.8	219	243	309	4.51e-38	134
C55_contig_822_1494	SARG|gi|445996729|ref|WP_000074584.1|	39.3	219	243	309	4.51e-38	134
C55_contig_822_1494	SARG|gi|1043490477|ref|WP_065382463.1|	39.3	219	243	309	6.33e-38	133
C55_contig_822_1494	SARG|gi|895736250|emb|COF64653.1|	39.3	219	243	309	6.33e-38	133
C55_contig_822_1509	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.1	222	224	255	2.34e-63	196
C55_contig_822_1509	SARG|gb|AAV85982.1|ARO:3000535|macB	44.6	224	224	644	1.60e-60	199
C55_contig_822_1509	SARG|gi|507086196|ref|WP_016156937.1|	48.2	222	224	648	4.76e-59	195
C55_contig_822_1509	SARG|gi|922960663|ref|WP_053388845.1|	48.2	220	224	648	6.64e-59	195
C55_contig_822_1509	SARG|gi|504542119|ref|WP_014729221.1|	47.7	220	224	647	9.13e-59	194
C55_contig_822_1509	SARG|gi|757799695|ref|WP_043016897.1|	48.2	220	224	648	9.27e-59	194
C55_contig_822_1509	SARG|gi|1045891604|ref|WP_065554100.1|	48.2	220	224	648	9.27e-59	194
C55_contig_822_1509	SARG|gi|507082903|ref|WP_016153652.1|	48.2	220	224	648	9.27e-59	194
C55_contig_822_1509	SARG|gi|740856590|ref|WP_038641842.1|	48.2	220	224	648	9.27e-59	194
C55_contig_822_1509	SARG|gi|851922185|ref|WP_048218206.1|	48.2	220	224	648	9.27e-59	194
C55_contig_822_1511	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	219	216	220	2.18e-39	134
C55_contig_822_1511	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.4	218	216	219	5.95e-39	132
C55_contig_822_1511	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.4	218	216	220	6.12e-39	132
C55_contig_822_1511	SARG|ZP_02848503	34.9	218	216	221	6.28e-39	132
C55_contig_822_1511	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.4	218	216	220	8.63e-39	132
C55_contig_822_1511	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	216	216	219	2.36e-38	131
C55_contig_822_1511	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.7	227	216	232	4.50e-35	123
C55_contig_822_1511	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.7	227	216	232	4.50e-35	123
C55_contig_822_1511	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	32.6	221	216	223	7.84e-34	119
C55_contig_822_1511	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.3	229	216	231	1.35e-33	119
C55_contig_822_1512	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.1	207	405	381	6.35e-19	86.7
C55_contig_822_1512	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.1	207	405	381	6.35e-19	86.7
C55_contig_822_1512	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.4	205	405	381	3.83e-18	84.3
C55_contig_822_1512	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.7	207	405	381	3.83e-18	84.3
C55_contig_822_1512	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.4	205	405	381	3.83e-18	84.3
C55_contig_822_1512	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.7	207	405	381	3.83e-18	84.3
C55_contig_822_1512	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	24.2	211	405	380	5.12e-18	84.0
C55_contig_822_1512	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.2	211	405	380	5.12e-18	84.0
C55_contig_822_1512	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.4	205	405	381	9.36e-18	83.2
C55_contig_822_1512	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.4	205	405	381	9.36e-18	83.2
C55_contig_822_1535	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	28.5	316	466	593	7.80e-22	97.4
C55_contig_822_1550	SARG|gi|1006223553|ref|WP_061745579.1|	23.5	425	444	451	1.02e-32	127
C55_contig_822_1550	SARG|ZP_03986195	24.2	426	444	451	1.92e-32	127
C55_contig_822_1550	SARG|gi|446573695|ref|WP_000651041.1|	24.2	426	444	451	1.92e-32	127
C55_contig_822_1550	SARG|gi|686432388|ref|WP_031921070.1|	23.9	426	444	451	2.64e-32	126
C55_contig_822_1550	SARG|gi|446573690|ref|WP_000651036.1|	23.9	426	444	451	6.77e-32	125
C55_contig_822_1550	SARG|gi|686408548|ref|WP_031913080.1|	23.7	426	444	451	9.28e-32	125
C55_contig_822_1550	SARG|gi|686304329|ref|WP_031867798.1|	23.7	426	444	451	9.28e-32	125
C55_contig_822_1550	SARG|YP_302230	24.4	427	444	451	6.09e-31	122
C55_contig_822_1550	SARG|gb|CAE00499.1|ARO:3003835|cdeA	21.9	420	444	441	1.28e-25	107
C55_contig_822_1672	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.1	1232	1242	1162	0.0	1215
C55_contig_822_1672	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	53.1	1230	1242	1186	0.0	1178
C55_contig_822_1672	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	53.1	1230	1242	1186	0.0	1178
C55_contig_822_1681	NCBI|CBE03766.1|1|1|nimB-Cd|nimB-Cd||1|NITROIMIDAZOLE|NITROIMIDAZOLE|putative_5-nitroimidazole_reductase_NimB-Cd|AMR|nitroimidazole	47.4	156	155	155	2.46e-40	132
C55_contig_822_1681	NCBI|WP_005812825.1|1|1|nimJ|nimJ|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimJ|AMR|nitroimidazole	32.5	157	155	165	1.32e-22	87.0
C55_contig_822_1700	SARG|NP_878015	36.2	254	316	322	9.37e-35	127
C55_contig_822_1700	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	34.6	295	316	337	3.43e-34	126
C55_contig_822_1700	SARG|gi|738848198|ref|WP_036737307.1|	34.6	254	316	323	1.91e-33	124
C55_contig_822_1700	SARG|KF478993.1.gene2.p01	33.0	276	316	350	3.20e-33	124
C55_contig_822_1700	SARG|AAR37059	34.5	281	316	323	7.22e-33	122
C55_contig_822_1700	SARG|AAD51059	34.2	281	316	323	1.40e-32	122
C55_contig_822_1700	SARG|AAD41881	34.3	289	316	323	1.40e-32	122
C55_contig_822_1700	SARG|gi|552942232|ref|WP_023043160.1|	33.6	289	316	323	1.42e-31	119
C55_contig_822_1700	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	32.6	307	316	351	1.70e-31	119
C55_contig_822_1700	SARG|CAB61228	35.1	259	316	322	7.28e-31	117
C55_contig_822_1716	SARG|gi|751264306|ref|WP_040974017.1|	38.8	219	255	646	1.64e-43	154
C55_contig_822_1716	SARG|gi|985815823|ref|WP_060876116.1|	38.1	215	255	646	3.12e-43	154
C55_contig_822_1716	SARG|YP_002239469	38.1	215	255	646	3.12e-43	154
C55_contig_822_1716	SARG|gi|695840638|ref|WP_032753940.1|	38.1	215	255	646	3.12e-43	154
C55_contig_822_1716	SARG|gi|556492128|ref|WP_023339842.1|	38.1	215	255	646	3.12e-43	154
C55_contig_822_1716	SARG|gi|556337683|ref|WP_023297316.1|	38.6	215	255	646	4.31e-43	153
C55_contig_822_1716	SARG|gi|763399392|ref|WP_044256358.1|	37.9	219	255	648	4.38e-43	153
C55_contig_822_1716	SARG|gi|852138723|ref|WP_048293411.1|	38.1	215	255	646	5.95e-43	153
C55_contig_822_1716	SARG|gi|1000904163|ref|WP_061155197.1|	38.1	215	255	646	5.95e-43	153
C55_contig_822_1716	SARG|gi|765283866|ref|WP_044612790.1|	38.1	215	255	646	5.95e-43	153
